Lectus adds neuropathic pain candidate to pipeline

Lectus Therapeutics, a UK drug discovery and development firm focused on ion channel modulators, has advanced a novel orally-active modulator  of N-type ion channels from research into development for neuropathic  pain. The move follows Lectus' series A financing round completed in  2006 and led by Sofinnova Partners, which enabled the company to  establish its pipeline.

Given the lack of recent industry success in the ion channels field,  Lectus says that its approach to selectively target ion channel  accessory proteins could represent a potential breakthrough in this  challenging area.